Myopia

A persistent measurement gap in preclinical myopia research is the conflation of refractive, structural, and functional visual endpoints. Refractive error – the diopter value that defines myopia clinically – is not the same as corneal curvature, which reflects anterior-segment optics and growth but not the full refractive system. Neither measurement captures whether the visual circuit – from retina through optic nerve to the brainstem optomotor pathway – is functionally intact in models where axial elongation is severe enough to produce secondary tractional injury. In genetic and pharmacological myopia models, changes in corneal curvature and changes in refractive state can diverge, making dual measurement essential for distinguishing corneal from axial contributions to the refractive phenotype. In high-myopia models with documented optic nerve involvement, neither refractive nor structural measurements detect functional RGC loss; only a direct functional acuity measurement via the optomotor reflex can capture this.

The practical barrier has historically been the need to use separate instruments, separate sessions, and different operators for each measurement type, introducing variability and making true longitudinal multi-endpoint studies difficult. Automated, non-contact instruments that can be used sequentially on awake, unrestrained animals within a single session address this directly.

Genetic studies of myopia face a phenotyping bottleneck: linking genotype to ocular phenotype requires objective, quantitative measurements that are sufficiently precise to detect the effect sizes typical of individual loci (often fractions of a diopter or sub-millimetre changes in corneal radius). Traditional manual refractive measurements in rodents are operator-dependent and poorly reproducible at this resolution. Retinoscopy and autorefraction methods developed for human clinical use are not directly transferable to small-animal eyes without calibration to the very different optical geometry of the rodent eye.

An additional challenge in genetic models is that different genes may independently affect corneal curvature, axial length, vitreous chamber depth, or lens power, with downstream effects on refractive error that partially cancel or amplify depending on which parameter is perturbed. Without separate corneal and refractive measurements, these contributions are conflated in the final diopter value. Novel genetic mechanisms – including lysosomal ECM proteolysis (cathepsin H) and retinal epitranscriptomic regulation (ALKBH5 m6A demethylation) – may have effects confined to specific ocular compartments that are separable only by multi-endpoint phenotyping.

Oxidative stress is increasingly recognised as a convergent amplifier of myopia progression. In the sclera, reactive oxygen species impair fibroblast function and accelerate collagen degradation, reducing scleral stiffness and permitting greater axial elongation under normal intraocular pressure. In the RPE, oxidative damage disrupts the normal signalling role of the RPE in modulating choroidal thickness and scleral remodelling signals. Ferroptosis – a recently characterised form of iron-catalysed, lipid-peroxidation-driven cell death – adds a further oxidative mechanism that may operate in the RPE and photoreceptors of myopic eyes, and is distinct from classical apoptosis in both its mechanism and its pharmacological inhibitors.

The translational challenge for nutraceutical myopia therapies is demonstrating that the protective effect is (a) dose-dependent, (b) measurable as a functional refractive change rather than only a histological or biochemical endpoint, and (c) achievable with a practically deliverable formulation. Conventional measurement endpoints for these studies – manual retinoscopy, cycloplegic autorefraction adapted from human instruments – are not optimised for the precision required to detect sub-diopter treatment differences in rodent eyes. A further challenge is drug delivery to the posterior segment: topical administration of hydrophilic compounds achieves limited penetration to the sclera and RPE, making advanced delivery platforms such as nanoparticle-loaded exosomes potentially necessary for therapeutic effect at lower doses.

For a broader overview of antioxidant and nutritional compounds in myopia biology, see Myopia, Refractive Development and Eye Growth. For the molecular and epigenetic mechanisms upstream of these interventions, see the same resource.

In preclinical models that progress to extreme axial elongation – including certain inherited mouse lines and long-duration FDM paradigms – the biological damage extends beyond the refractive phenotype. Progressive axial elongation stretches the posterior pole, deforms the optic nerve head, and subjects RGC axons to chronic mechanical and ischaemic stress that is mechanistically overlapping with normal-tension glaucoma. This convergence between high myopia and glaucomatous RGC neurodegeneration is clinically significant: high myopia is an independent risk factor for normal-tension glaucoma, and the two conditions share the final common pathway of progressive RGC loss and optic nerve atrophy.

In such cross-context models, measuring only refractive error with the Photorefractor misses the secondary circuit-level pathology entirely. Histological endpoints (RGC counts, optic nerve cross-section) are terminal and unsuitable for longitudinal monitoring. OptoDrum optomotor testing provides a non-invasive, longitudinal, functional correlate of RGC pathway integrity that complements the structural refractive measurements in the same animal at the same time point. For inherited models with overlapping rare-disease phenotypes, this multi-endpoint approach is also relevant to the Rare and Inherited CNS and Eye Disorders and Retinal Degeneration and Inherited Retinal Disease contexts. For the aging dimension of progressive axial elongation, see Systemic Aging and CNS Decline. For focused treatment of the glaucoma-optic nerve intersection, see Glaucoma and Optic Nerve Neurodegeneration. The optic nerve damage cluster is further discussed at optic nerve damage and the RGC dysfunction dimension at retinal ganglion cell dysfunction.

Studies that measure refractive error at a single time point or at widely spaced intervals risk misclassifying the phase of myopia progression at which an intervention was applied, leading to underestimation of efficacy (if measured during a natural plateau) or apparent treatment failure (if the intervention slows initiation but not rapid progression). Wen et al. (2024) established empirically that myopia progression in rodent models follows a nonlinear trajectory with distinct phases; without this framework, single-time-point studies cannot distinguish phase-specific from phase-independent treatment effects.

Molecular brake targets add a further layer of complexity. BMP2 signalling regulates scleral fibroblast ECM synthesis and is active during the early remodelling phase; modulating it during the plateau phase may have little effect even if the compound is biologically potent. The mTOR/HIF-1α axis governs scleral metabolic adaptation to the mechanical demands of the elongating eye and may be relevant across phases but particularly active during rapid elongation. Matching the temporal profile of molecular pathway activity to the trajectory phases identified by Photorefractor is essential for designing intervention studies with sufficient power to detect biologically meaningful effects.

For a broader overview of pharmacological intervention methods including optical and pharmacological comparators, see Myopia, Refractive Development and Eye Growth.